Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
synthetic lethality
Biotech
Roche axes Repare's oncology drug days after starting study
Days after triggering a $40 million payment, Roche told Repare it is ending the deal after a review of its pipeline and “evolving external factors.”
Nick Paul Taylor
Feb 13, 2024 5:51am
Merck inks $169M PARP1 deal, escalating challenge to AstraZeneca
Oct 30, 2023 8:40am
Day One jets off with Sprint's VRK1 program for up to $316M
Aug 16, 2023 10:47am
Roche inks KSQ deal to expand stable of synthetic lethal assets
Jul 13, 2023 9:20am
Roche pays Repare $125M to join Big Pharma peers in cancer race
Jun 2, 2022 8:27am
Pfizer bets $25M on Zentalis, signs up to support cancer trials
Apr 27, 2022 7:44am